Tolaney, S. M., Li, T., Mittendorf, E. A., Shapiro, G. I., Dougan, S. K., Tayob, N., . . . Williams, A. J. Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer. BMJ Publishing Group.
Chicago Style (17th ed.) CitationTolaney, Sara M., et al. Phase I Study of Ribociclib (CDK4/6 Inhibitor) with Spartalizumab (PD-1 Inhibitor) with and Without Fulvestrant in Metastatic Hormone Receptor-positive Breast Cancer or Advanced Ovarian Cancer. BMJ Publishing Group.
MLA (9th ed.) CitationTolaney, Sara M., et al. Phase I Study of Ribociclib (CDK4/6 Inhibitor) with Spartalizumab (PD-1 Inhibitor) with and Without Fulvestrant in Metastatic Hormone Receptor-positive Breast Cancer or Advanced Ovarian Cancer. BMJ Publishing Group.